AtriCure (NASDAQ:ATRC – Free Report) had its target price decreased by JPMorgan Chase & Co. from $51.00 to $46.00 in a ...

AtriCure (NASDAQ:ATRC – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Needham & Company LLC in a research note issued to investors on Thursday,Benzinga reports.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atricure (ATRC – Research Report) and Journey ...

Barclays said in a note Monday that it sees attractive entry points in MedTech stocks, as recent weakness in some sector ...

Canaccord lowered the firm’s price target on AtriCure (ATRC) to $52 from $66 and keeps a Buy rating on the shares. The firm updated its model ...

MASON, Ohio, March 12, 2025--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and ...

Shaping Responsible Governance of AI and Emerging Technologies in a Future Digital Economy The Advanced Technology Research ...

Find investment ideas for your portfolio with the latest stock picks from Barron’s below. These picks are the product of the Barron’s newsroom and are our best ideas based on original ...

Her expertise is in personal finance and investing, and real estate. A stock-for-stock merger occurs when shares of one company are traded for another during an acquisition. Shareholders can trade ...